Lundbeck
Lundbeck sells $100m portfolio
January 22, 2013Sales and Marketing Lundbeck, OTC, Panhematin, Recordati
Italian pharma group Recordati has paid $80 million to Lundbeck for a portfolio of products primarily aimed at the US …
Lundbeck appoints new global pricing and market access VP
January 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eggert, Jaszewski, Lundbeck
Barbara Jaszewski, has been appointed vice president of global pricing and market access at Lundbeck. She will be in charge …
Lundbeck opens first Asian manufacturing plant
November 14, 2012Manufacturing and Production China, Lundbeck
Lundbeck has officially opened its first manufacturing facility in China and says it plans to launch three new drugs there …
API supply issues lead Lundbeck to drop cancer drug
September 18, 2012Manufacturing and Production Elspar, Lundbeck, Ovation
Danish firm Lundbeck has decided to discontinue supplies of its leukaemia drug Elspar from December after struggling to find a …
Lundbeck makes two senior appointments
August 22, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Eggert, Klaus Abel, Lundbeck
Lundbeck has appointed Andreas Eggert (pictured) as senior vice president for global product strategy, and Klaus Abel as vice president …
Ireland agrees deal on medicines
June 28, 2012Business Services, Sales and Marketing AstraZeneca, IPHA, Ireland, Lundbeck, Novartis, pricing
Ireland’s pharmaceutical industry has agreed a deal with the country’s government which breaks a deadlock over prices and access. The …
Lundbeck to slash 600 jobs in Europe
June 15, 2012Sales and Marketing Cipralex, Europe, Lundbeck, austerity, cuts
Lundbeck will cut 600 jobs from its operations in Europe as its Cipralex parent expiry continues to erode revenue. The …
Lundbeck’s Alzheimer’s drug shows promise
May 29, 2012Research and Development, Sales and Marketing Alzheimer's, Lundbeck
Lundbeck’s Alzheimer’s candidate Lu AE58054 has shown signs in a phase II study of helping patients’ mental activity. Sufferers receiving …
Lundbeck appoints European leaders
February 10, 2012Medical Communications, Sales and Marketing Cipralex, Lundbeck
Lundbeck has appointed two new regional vice presidents for European markets, in time for new drug launches.João Rocha is to …
Lundbeck gets award for manufacturing excellence
January 18, 2012Manufacturing and Production Lundbeck, Shingo, manufacturing
Efforts by Lundbeck to boost the productivity of its manufacturing operations have borne fruit, with the company cutting costs by …
Lundbeck launches bipolar drug Sycrest in the UK
January 17, 2012Sales and Marketing Lundbeck, Saphris, Sycrest, zyprexa
Lundbeck has launched Sycrest in the UK for the treatment of acute attacks of bipolar I disorder. Sycrest (asenapine) is …
Otsuka and UCB scale down collaboration
January 16, 2012Research and Development, Sales and Marketing Lundbeck, Otsuka, UCB
Otsuka and UCB have scaled back the scope of their collaboration, and will now focus on developing drugs for the …
Lundbeck and Otsuka to collaborate in CNS
November 11, 2011Research and Development, Sales and Marketing Abilify, CNS, Lundbeck, Otsuka
Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a …
Lundbeck appoints two new R&D vice presidents
November 1, 2011Research and Development Lundbeck, R&D
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents of its research and development organisation. The new …
Lundbeck establishes research centre in China
October 18, 2011Research and Development Brain disorders, CNS, China, Lundbeck, Shanghai, emerging markets
Lundbeck has set up a new research centre in China, joining a wave of pharma companies investing in the region. The …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
